Irritable Bowel Syndrome - Pipeline Review, H1 2015
Summary
Global Markets Direct’s, ‘Irritable Bowel Syndrome - Pipeline Review, H1 2015’, provides an overview of the Irritable Bowel Syndrome’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Irritable Bowel Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Irritable Bowel Syndrome and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Irritable Bowel Syndrome
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Irritable Bowel Syndrome and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Irritable Bowel Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Irritable Bowel Syndrome pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Irritable Bowel Syndrome
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Irritable Bowel Syndrome pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Introduction
- Global Markets Direct Report Coverage
- Irritable Bowel Syndrome Overview
- Therapeutics Development
- Pipeline Products for Irritable Bowel Syndrome - Overview
- Pipeline Products for Irritable Bowel Syndrome - Comparative Analysis
- Irritable Bowel Syndrome - Therapeutics under Development by Companies
- Irritable Bowel Syndrome - Pipeline Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Irritable Bowel Syndrome - Products under Development by Companies
- Irritable Bowel Syndrome - Companies Involved in Therapeutics Development
- A. Menarini Industrie Farmaceutiche Riunite Srl
- Actavis Plc
- Alba Therapeutics Corporation
- Alfa Wassermann S.p.A
- Ardelyx, Inc.
- Astellas Pharma Inc.
- Dong-A Socio Group
- GIcare Pharma Inc
- Hanmi Pharmaceuticals, Co. Ltd.
- ImmusanT, Inc.
- Ironwood Pharmaceuticals, Inc.
- Juno Therapeutics Inc.
- Ono Pharmaceutical Co., Ltd.
- Protagonist Therapeutics Inc.
- RaQualia Pharma Inc.
- SK Biopharmaceuticals Co., Ltd.
- SK Chemicals Co., Ltd.
- Sumitomo Dainippon Pharma Co., Ltd.
- Synergy Pharmaceuticals, Inc.
- Synthetic Biologics, Inc.
- Takeda Pharmaceutical Company Limited
- Yuhan Corporation
- Irritable Bowel Syndrome - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- (Bacillus subtilis + mosapride + Streptococcus faecium) - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- ASP-1017 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- ASP-7147 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Blautix - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- DA-6886 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- DSP-6952 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- eluxadoline - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- GIC-1001 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- ibodutant - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- larazotide acetate - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- linaclotide - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Monoclonal Antibody to Antagonize M3 for Irritable Bowel Syndrome - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Nexvax-2 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- ONO-2952 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- plecanatide - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- relenopride hydrochloride - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- rifaximin - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- RQ-00202730 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- RQ-00310941 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- SKI-3246 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Small Molecules to Inhibit 5-HT2B and 5-HT7 Receptors for IBS and Migraine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Small Molecules to Inhibit SMURF2 for Fibrosis, Oncology and IBD - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- SYN-010 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Synthetic Peptides for Gastrointestinal Disorders - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Synthetic Peptides for Irritable Bowel Syndrome and Inflammatory Bowel Disease - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- TAK-480 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- tenapanor hydrochloride - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- YH-12852 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Irritable Bowel Syndrome - Recent Pipeline Updates
- Irritable Bowel Syndrome - Dormant Projects
- Irritable Bowel Syndrome - Discontinued Products
- Irritable Bowel Syndrome - Product Development Milestones
- Featured News & Press Releases
- May 27, 2015: Actavis Receives FDA Approval for VIBERZI (eluxadoline) for the Treatment of Irritable Bowel Syndrome with Diarrhea in Adults
- May 20, 2015: 4D pharma Provides Research Update on Clinical Development Of Blautix
- May 19, 2015: Ardelyx Presents Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients at Digestive Disease Week 2015
- May 18, 2015: Synthetic Biologics' Novel SYN-010 Preclinical Data Featured in Digestive Disease Week Poster
- Feb 17, 2015: Synthetic Biologics Announces Poster Presentation of C-IBS Candidate Therapy Data at Digestive Disease Week 2015
- Jan 05, 2015: 4D pharma Provides Research Update
- Dec 18, 2014: Synergy Pharmaceuticals Initiates First Phase 3 Clinical Trial of Plecanatide in Patients with Irritable Bowel Syndrome with Constipation
- Nov 20, 2014: Ironwood Earns $15 Million Milestone from Astellas upon Initiation of Enrollment in Linaclotide Phase III IBS-C Clinical Trial in Japan
- Nov 04, 2014: Ironwood Pharmaceuticals Initiates Phase III Trial of 72 mcg Linaclotide in Adult Patients with Chronic Idiopathic Constipation
- Oct 21, 2014: Synergy Pharmaceuticals Presents Positive Phase 2b Study Results for Plecanatide in Patients with Irritable Bowel Syndrome with Constipation
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products under Development for Irritable Bowel Syndrome, H1 2015
- Number of Products under Development for Irritable Bowel Syndrome - Comparative Analysis, H1 2015
- Number of Products under Development by Companies, H1 2015
- Number of Products under Development by Companies, H1 2015 (Contd..1)
- Comparative Analysis by Late Stage Development, H1 2015
- Comparative Analysis by Clinical Stage Development, H1 2015
- Comparative Analysis by Early Stage Development, H1 2015
- Products under Development by Companies, H1 2015
- Products under Development by Companies, H1 2015 (Contd..1)
- Irritable Bowel Syndrome - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2015
- Irritable Bowel Syndrome - Pipeline by Actavis Plc, H1 2015
- Irritable Bowel Syndrome - Pipeline by Alba Therapeutics Corporation, H1 2015
- Irritable Bowel Syndrome - Pipeline by Alfa Wassermann S.p.A, H1 2015
- Irritable Bowel Syndrome - Pipeline by Ardelyx, Inc., H1 2015
- Irritable Bowel Syndrome - Pipeline by Astellas Pharma Inc., H1 2015
- Irritable Bowel Syndrome - Pipeline by Dong-A Socio Group, H1 2015
- Irritable Bowel Syndrome - Pipeline by GIcare Pharma Inc, H1 2015
- Irritable Bowel Syndrome - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2015
- Irritable Bowel Syndrome - Pipeline by ImmusanT, Inc., H1 2015
- Irritable Bowel Syndrome - Pipeline by Ironwood Pharmaceuticals, Inc., H1 2015
- Irritable Bowel Syndrome - Pipeline by Juno Therapeutics Inc., H1 2015
- Irritable Bowel Syndrome - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015
- Irritable Bowel Syndrome - Pipeline by Protagonist Therapeutics Inc., H1 2015
- Irritable Bowel Syndrome - Pipeline by RaQualia Pharma Inc., H1 2015
- Irritable Bowel Syndrome - Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2015
- Irritable Bowel Syndrome - Pipeline by SK Chemicals Co., Ltd., H1 2015
- Irritable Bowel Syndrome - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015
- Irritable Bowel Syndrome - Pipeline by Synergy Pharmaceuticals, Inc., H1 2015
- Irritable Bowel Syndrome - Pipeline by Synthetic Biologics, Inc., H1 2015
- Irritable Bowel Syndrome - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015
- Irritable Bowel Syndrome - Pipeline by Yuhan Corporation, H1 2015
- Assessment by Monotherapy Products, H1 2015
- Assessment by Combination Products, H1 2015
- Number of Products by Stage and Target, H1 2015
- Number of Products by Stage and Mechanism of Action, H1 2015
- Number of Products by Stage and Route of Administration, H1 2015
- Number of Products by Stage and Molecule Type, H1 2015
- Irritable Bowel Syndrome Therapeutics - Recent Pipeline Updates, H1 2015
- Irritable Bowel Syndrome - Dormant Projects, H1 2015
- Irritable Bowel Syndrome - Dormant Projects (Contd..1), H1 2015
- Irritable Bowel Syndrome - Dormant Projects (Contd..2), H1 2015
- Irritable Bowel Syndrome - Dormant Projects (Contd..3), H1 2015
- Irritable Bowel Syndrome - Discontinued Products, H1 2015
- Irritable Bowel Syndrome - Discontinued Products (Contd..1), H1 2015
- List of Figures
- Number of Products under Development for Irritable Bowel Syndrome, H1 2015
- Number of Products under Development for Irritable Bowel Syndrome - Comparative Analysis, H1 2015
- Number of Products under Development by Companies, H1 2015
- Comparative Analysis by Clinical Stage Development, H1 2015
- Comparative Analysis by Early Stage Products, H1 2015
- Assessment by Monotherapy Products, H1 2015
- Number of Products by Top 10 Targets, H1 2015
- Number of Products by Stage and Top 10 Targets, H1 2015
- Number of Products by Top 10 Mechanism of Actions, H1 2015
- Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
- Number of Products by Top 10 Routes of Administration, H1 2015
- Number of Products by Stage and Top 10 Routes of Administration, H1 2015
- Number of Products by Top 10 Molecule Types, H1 2015
- Number of Products by Stage and Top 10 Molecule Types, H1 2015